Development of engineered cells for implantation in gene therapy

Advanced Drug Delivery Reviews

Volumn 33, Issue 1-2, 1998, Pages 31-43

  Chang, Patricia L ^a   Bowie, Kelly MacMillan ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Alginate; Differentiation; Dwarfism; Gene therapy; Growth hormone; Lysosomal storage diseases; Myoblast; Myotube

Indexed keywords

CELLS; DISEASES; GENE TRANSFER; HORMONES; MEDICINE;

CELL ENGINEERING; GENE THERAPY; GENETIC DISEASES;

GENETIC ENGINEERING;

GENE PRODUCT;

CELL DIFFERENTIATION; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC ENGINEERING; HUMAN; MOUSE; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0032479743     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00018-0     Document Type: Review

References (72)

1. [1] G. Ross, R. Erickson, D. Knorr, A.G. Motulsky, R. Parkman, J. Samulski, S.E. Straus, B.R. Smith, Gene therapy in the United States: a five year status report, Hum. Gene Ther. 7 (1996) 1781-1790.
2. [2] H.M. Blau, M.L. Springer, Gene therapy - A novel form of drug delivery, N. Engl. J. Med. 333 (1995) 1204-1207.
3. [3] P.L. Chang, Nonautologous somatic gene therapy, in: P.L. Chang (Ed.), Somatic Gene Therapy, CRC Press, Boca Raton, FL, 1995, pp. 203-223.
4. [4] T.L. Stockley, P.L. Chang, Nonautologous somatic gene therapy: a novel approach to drug delivery, Drug News Perspect. 10 (1997) 331-340.
5. [5] J.M. Rappeport, Indications and applications of bone marrow transplantation, in: R. Hoffman, E.J. Benz Jr., S.J. Shattil, B. Furie, H.J. Cohen (Eds.), Hematology: Basic Principles and Practice, Churchill Livingstone, New York, NY, 1991, pp. 230-242.
6. [6] D.B. Kohn, K.I. Weinberg, J.A. Nolta, L.N. Heiss, C. Lenarsky, G.M. Crooks, M.E. Hanley, G. Annett, J.S. Brooks, A. El-Khoureiy, K. Lawrence, S. Wells, R.C. Moen, J. Bastian, D.E. Williams-Herman, M. Elder, D. Wara, T. Bowen, M.S. Hershfield, C.A. Mullen, M. Blaese, R. Parkman, Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency, Nat. Med. 1(10) (1995) 1017-1023.
7. [7] R.M. Blaese, K.W. Culver, A.D. Miller, C.S. Carter, T. Fleisher, M. Clerici, G. Shearer, L. Chang, Y. Chiang, P. Tolstoshev, J.J. Greenblatt, S.A. Rosenberg, H. Klein, M. Berger, C.A. Mullen, W.J. Ramsey, L. Muul, R.A. Morgan, W.F. Anderson, T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years, Science 270 (1995) 475-480.
8. [8] C. Bordignon, L.D. Notarangelo, N. Nobili, G. Ferrari, G. Casorati, P. Panina, E. Mazzolari, D. Maggioni, C. Rossi, P. Servida, A.G. Ugazio, F. Mavilio, Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients, Science 270 (1995) 470-475.
9. [9] R.F. Seldon, M.J. Skoskiewicz, K. Burke Howie, P.S. Russell, H.M. Goodman, Implantation of genetically engineered fibroblasts into mice: implications for gene therapy, Science 236 (1987) 714-718.
10. [10] P.L. Chang, J.P. Capone, G.M. Brown, Autologous fibroblast implantation: feasibility and potential problems in gene replacement therapy, Mol. Biol. Med. 7 (1990) 461-470.
11. [11] J. Seppen, K. Tada, R. Ottenhoff, K. Sengupta, N.R. Chowdhury, J.R. Chowdhury, P.J. Bosma, R.P.J. Elferink, Transplantation of Gunn rats with autologous fibroblasts expressing bilirubin UDP-glucuronosyltransferase: correction of genetic deficiency and tumor formation, Hum. Gene Ther. 8 (1997) 27-36.
12. [12] M. Grossman, S.E. Raper, K. Kozarsky, E.A. Stein, J.F. Engelhardt, D. Muller, P.J. Lupien, J.M. Wilson, Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia, Nat. Genet. 6 (1994) 335-341.
13. [13] R.O. Snyder, C.H. Miao, G.A. Patijn, S.K. Spratt, O. Danos, D. Nagy, A.M. Gown, B. Winther, L. Meuse, L.K. Cohen, A.R. Thompson, M.A. Kay, Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors, Nat. Genet. 16 (1997) 270-276.
14. [14] K.A. Choate, D.A. Medalie, J.R. Morgan, P.A. Khavari, Corrective gene transfer in the human skin disorder lamellar ichthyosis, Nat. Med. 2 (1996) 1263-1267.
15. [15] E.S. Fenjves, J. Smith, S. Zaradic, L.B. Taichman, Systemic delivery of secreted protein by grafts of epidermal keratinocytes: prospects for keratinocyte gene therapy, Hum. Gene Ther. 5 (1994) 1241-1248.
16. [16] A.J. Gerrard, D.L. Hudson, G.G. Brownlee, F.M. Watt, Towards gene therapy for haemophilia B using primary human keratinocytes, Nat. Genet. 3 (1993) 180-183.
17. [17] E. Barr, J.M. Leiden, Systemic delivery of recombinant proteins by genetically modified myoblasts, Science 254 (1991) 1507-1509.
18. [18] S. Yao, K. Kurachi, Expression of human factor IX in mice after injection of genetically modified myoblasts, Proc. Natl. Acad. Sci. USA 89 (1992) 3357-3361.
19. [19] N. Naffakh, C. Pinset, D. Montarras, Z. Li, D. Paulin, O. Danos, J.M. Heard, Long-term secretion of therapeutic proteins from genetically modified skeletal muscles, Hum. Gene Ther. 7 (1996) 11-21.
20. [20] R.M. Shull, X. Lu, M.F. McEntee, R.M. Bright, K.A. Pepper, D.B. Kohn, Myoblast gene therapy in canine mucopolysaccharidosis I: abrogation by an immune response to L-iduronidase, Hum. Gene Ther. 7 (1996) 1595-1603.
21. [21] R.W. Herzog, J.N. Hagstrom, S.H. Kung, S.J. Tai, J.M. Wilson, K.J. Fisher, K.A. High, Stable gene transfer and expression of human blood coagulation factor IX after intramusclular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA 94 (1997) 5804-5809.
22. [22] E.M. Elder, M.T. Lotze, T.L. Whiteside, Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer, Hum. Gene Ther. 7 (1996) 479-487.
23. [23] H. Tahara, M.T. Lotze, P.D. Robbins, W.J. Storkus, L. Zitvogel, IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts, Hum. Gene Ther. 6 (1995) 1607-1624.
24. [24] R.G. Crystal, Transfer of genes to humans: early lessons and obstacles to success, Science 270 (1995) 404-410.
25. [25] S. Ishibashi, M.S. Brown, J.L. Goldstein, R.D. Gerard, R.E. Hammer, J. Herz, Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery, J. Clin. Invest. 92 (1993) 883-893.
26. [26] K.F. Kozarksy, D.R. McKinley, L.L. Austin, S.E. Raper, L.D. Stratford-Perricaudet, J.M. Wilson, In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses, J. Biol. Chem. 269 (1994) 13695-13702.
27. [27] J. Bennett, T. Tanabe, D. Sun, Y. Zeng, H. Kjeldbye, P. Gouras, A.M. Maguire, Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy, Nat. Med. 2(6) (1996) 649-654.
28. [28] J. Zabner, L.A. Couture, R.J. Gregory, S.M. Graham, A.E. Smith, M.J. Welsh, Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis, Cell 75 (1993) 207-216.
29. [29] R.G. Crystal, N.G. McElvaney, M.A. Rosenfeld, C. Chu, A. Mastrangeli, J.G. Hay, S.L. Brody, H.A. Jaffe, N.T. Eissa, C. Danel, Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis, Nat. Genet. 8 (1994) 42-50.
30. [30] M.R. Knowles, K.W. Hohneker, A. Zhou, J.C. Olsen, T.L. Noah, P.C. Hu, M.W. Leigh, J.F. Engelhardt, L.J. Edwards, K.R. Jones, M. Grossman, J.M. Wilson, L.G. Johnson, R.C. Boucher, A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patient with cystic fibrosis, N. Engl. J. Med. 333 (1995) 823-831.
31. [31] J.A. Wolff, R.W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, P.L. Felgner, Direct gene transfer into mouse muscle in vivo, Science 247 (1990) 1465-1468.
32. [32] S. Jiao, P. Williams, R.K. Berg, B.A. Hodgeman, L. Liu, G. Repetto, J.A. Wolff, Direct gene transfer into nonhuman primate myofibres in vivo, Hum. Gene Ther. 3 (1992) 21-33.
33. [33] H.L. Davis, B.A. Demeneix, B. Quantin, J. Coulombe, R.G. Whalen, Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle, Hum. Gene Ther. 4 (1993) 733-740.
34. [34] C. Wu, J.M. Wilson, G.Y. Wu, Targeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo, J. Biol. Chem. 264(29) (1989) 16985-16987.
35. [35] M. Tsukamoto, T. Ochiya, S. Yoshida, T. Sugimura, M. Terada, Gene transfer and expression in progeny after intravenous DNA injection into pregnant mice, Nat. Genet. 9 (1995) 243-248.
36. [36] N.J. Caplan, E.W.F.W. Alton, P.G. Middleton, J.R. Dorin, B.J. Stevenson, X. Gao, S.R. Durham, P.K. Jeffery, M.E. Hodson, C. Coutelle, L. Huang, D.J. Porteous, R. Williamson, D.M. Geddes, Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis, Nat. Med. 1(1) (1995) 39-46.
37. [37] L. Cao, Z. Zheng, Y. Zhao, Z. Jiang, Z. Liu, S. Chen, C. Zhou, X. Liu, Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex, Hum. Gene Ther. 6 (1995) 1497-1501.
38. [38] E.G. Nabel, Z. Yang, D. Muller, A.E. Chang, X. Gao, L. Huang, K.J. Cho, G.J. Nabel, Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma, Hum. Gene Ther. 5 (1994) 1089-1094.
39. [39] Y. Kaneda, K. Iwai, T. Uchida, Increased expression of DNA cointroduced with nuclear protein in adult rat liver, Science 243 (1989) 375-378.
40. [40] D.T. Curiel, S. Agarwal, E. Wagner, M. Cotten, Adenovirus enhancement of transferrin-polylysine mediated gene delivery, Proc. Natl. Acad. Sci. USA 88 (1991) 8850-8854.
41. [41] M. Cotten, E. Wagner, K. Zatloukal, S. Phillips, D. Curiel, J. Birnstiel, High-efficiency receptor-mediated delivery of small and large (48 kb) gene constructs using the endosome-disruption activity of defective or chemically-inactivated adenovirus particles, Proc. Natl. Acad. Sci. USA 89 (1992) 6094-6098.
42. [42] R.J. Cristiano, L.C. Smith, S.L.C. Woo, Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes, Proc. Natl. Acad. Sci. USA 90 (1993) 2122-2126.
43. [43] E. Wagner, K. Zatloukal, M. Cotten, H. Kirlappos, K. Mechtler, D.T. Curiel, M.L. Birnstiel, Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes, Proc. Natl. Acad. Sci. USA 89 (1992) 6099-6103.
44. [44] J.M. Wilson, M. Grossman, C.H. Wu, N.R. Chowdhury, G.Y. Wu, J.R. Chowdhury, Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein-deficient rabbits, J. Biol. Chem. 267 (1992) 963-967.
45. [45] P. Poncet, A. Panczak, C. Goupy, K. Gustafsson, C. Blanpied, G. Chavanel, R. Hirsch, F. Hirsch, Antifection: an antibody-mediated method to introduce genes into lymphoid cells in vitro and in vivo, Gene Ther. 3 (1996) 731-738.
46. [46] A. Sun, Microencapsulation of pancreatic islet cells: a bioartificial endocrine pancreas, Methods Enzymol. 137 (1998) 575-579.
47. [47] D.E. Awrey, M. Tse, G. Hortelano, P.L. Chang, Permeability of alginate microcapsules to secretory recombinant gene products, Biotechnol. Bioeng. 52 (1996) 472-484.
48. [48] G.A. King, A.J. Daugulis, P. Faulkner, M.F.A. Goosen, Alginate-polylysine microcapsules of controlled membrane molecular weight cutoff for mammalian cell culture engineering, Biotechnol. Prog. 3 (1987) 231-240.
49. [49] G.M. O'Shea, M.F.A. Goosen, A.M. Sun, Prolonged survival of transplanted islets of Langerhans encapsulated in a biocompatible membrane, Biochim. Biophys. Acta 804 (1984) 133-136.
50. [50] H. Wong, T.M.S. Chang, A novel two step procedure for immobilizing living cells in microcapsules for improving xenograft survival, Biomater. Artif. Cells Immobilization Biotechnol. 19(4) (1991) 687-697.
51. [51] M. Tse, H. Uludag, M.V. Sefton, P.L. Chang, Secretion of recombinant proteins from hydroxyethyl methacrylatemethyl methacrylate capsules, Biotechnol. Bioeng. 51 (1996) 271-280.
52. [52] P.L. Chang, N. Shen, A.J. Westcott, Delivery of recombinant gene products with microencapsulated cells in vivo, Hum. Gene Ther. 4 (1993) 433-440.
53. [53] C.J.D. Ross, P.L. Chang, Microencapsulation - A novel gene therapy for lysosomal storage diseases, in: W.M. Kuhtreiber, R.P. Lonza, W.L. Chick (Eds.), Handbook of Encapsulated Cell Technology and Therapeutics, Birkhauser, Boston, 1997, chapt. 28.
54. [54] D.A. Sassoon, Myogenic regulatory factors: dissecting their role and regulation during vertebrate embryogenesis, Dev. Biol. 156 (1993) 11-23.
55. [55] E.N. Olson, Interplay between proliferation and differentiation within the myogenic lineage, Dev. Biol. 154 (1992) 261-272.
56. [56] M. Crescenzi, D.H. Crouch, F. Tato, Transformation by myc prevents fusion but not biochemical differentiation of C2C12 myoblasts: mechanisms of phenotypic correction in mixed culture with normal cells, J. Cell Biol. 125(5) (1994) 1137-1145.
57. [57] H.T. Nguyen, R.M. Medford, B. Nadal-Ginard, Reversibility of muscle differentiation in the absence of commitment: analysis of a myogenic cell line temperature-sensitive for commitment, Cell 34 (1983) 281-293.
58. [58] K.M. Bowie, P.L. Chang, Differentiation of recombinant myoblasts in alginate microcapsules (in preparation).
59. [59] B.H. Devlin, I.R. Konigsberg, Re-entry into the cell cycle of differentiated skeletal myocytes, Dev. Biol. 95 (1983) 175-192.
60. [60] J.S. Chamberlain, J.B. Jaynes, S.D. Hauschka, Regulation of creatine kinase induction in differentiating mouse myoblasts, Mol. Cell. Biol. 5(3) (1985) 484-492.
61. [61] A. Shainberg, G. Yagil, D. Yaffe, Alterations of enzymatic activities during muscle differentiation in vitro, Dev. Biol. 25 (1971) 1-29.
62. [62] J.B. Miller, Myoblast diversity in skeletal myogenesis: how much and to what end?, Cell 69 (1992) 1-3.
63. [63] D.C. Ludolph, S.F. Konieczny, Transcription factor families: muscling in on the myogenic program, FASEB J. 9 (1995) 1595-1604.
64. [64] H.M. Blau, J. Dhawan, G.K. Pavlath, Myoblasts in pattern formation and gene therapy, Trends Genet. 9 (1993) 269-274.
65. [65] M.E. Mangan, J.B. Olmsted, A muscle-specific variant of microtubule-associated protein 4 (MAP4) is required in myogenesis, Development 122 (1996) 771-781.
66. 2+ stores in myoblast fusion, Exp. Cell Res. 223 (1996) 301-307.
67. [67] D. Peck, F.S. Walsh, Differential effects of over-expressed neural cell adhesion molecule isoforms on myoblast fusion, J. Cell Biol. 123 (1993) 1587-1595.
68. [68] M. Zeschnigk, D. Kozian, C. Kuch, M. Schmoll, A. Starzinski-Powitz, Involvement of M-cadherin in terminal differentiation of skeletal muscle cells, J. Cell Sci. 108 (1995) 2973-2981.
69. [69] S. Fazeli, D.J. Wells, C. Hobbs, F.S. Walsh, Altered secondary myogenesis in transgenic animals expressing the neural cell adhesion molecule under the control of a skeletal muscle-actin promoter, J. Cell Biol. 135 (1996) 241-251.
70. [70] G. Hortelano, A. Al-Hendy, F.A. Ofosu, P.L. Chang, Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of Hemophilia B, Blood 87 (1996) 5095-5103.
71. [71] C. Lin, S.-C. Lin, C.-P. Chang, M.G. Rosenfeld, Pit-1-dependent expression of the receptor for growth hormone releasing factor mediates pituitary cell growth, Nature 360 (1992) 767-768.
72. [72] A. Al-Hendy, G. Hortelano, G.S. Tannenbaum, P.L. Chang, Allogeneic somatic gene therapy: correction of growth hormone deficiency in mice with microencapsulated non-autologous myoblasts, Hum. Gene Ther. 6 (1995) 165-175.